Brandi R Page1, Edward G Shaw1, Lingyi Lu1, David Bryant1, David Grisell1, Glenn J Lesser1, Drew C Monitto1, Michelle J Naughton1, Stephen R Rapp1, Steven R Savona1, Sunjay Shah1, Doug Case1, Michael D Chan1. 1. Department of Radiation Oncology, Medical Center Blvd, Wake Forest School of Medicine, Winston-Salem, North Carolina (B.R.P., E.G.S., M.D.C.); Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina (L.L., D.C.); Department of Medical Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina (G.J.L.); Via Christi Cancer Center, Witchita, Kansas (D.B.); Greenville Health System Cancer Institute, Greenville, South Carolina (D.G.); Spartanburg Regional Healthcare System, Spartanburg, South Carolina (D.C.M.); Hofstra Northshore-LIJ School of Medicine, New Hyde Park, New York (S.R.S.); Christiana Care CCOP, Newark, Delaware (S.S.); Wake Forest University Department of Geriatric Medicine, Memory Assessment Clinic Counseling Center, Winston-Salem, North Carolina (E.G.S.); Department of Medicine, Ohio State University, Columbus, Ohio (M.J.N.); Department of Psychiatry, Wake Forest School of Medicine, Winston-Salem, North Carolina (S.R.R.).
Abstract
BACKGROUND: Common acute-term side effects of brain radiotherapy (RT) include fatigue, drowsiness, decreased physical functioning, and decreased quality of life (QOL). We hypothesized that armodafinil (a wakefulness-promoting drug known to reduce fatigue and increase cognitive function in breast cancer patients receivingchemotherapy) would result in reduced fatigue and sleepiness for patients receiving brain RT. METHODS: A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect. RESULTS:From September 20, 2010, to October 20, 2012, 54 participants enrolled with 80% retention and 94% self-reported compliance. There were no grade 4-5 toxicities, and the incidence of grade 2-3 toxicities was similar between treatment arms, the most common of which were anxiety and nausea (15%), headaches (19%), and insomnia (20%). There were no statistically significant differences in end-RT or 4 week post-RT outcomes between armodafinil and placebo in any outcomes (Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue, Brief Fatigue Inventory, Epworth Sleepiness Scale, FACT-Brain, and FACIT-cognitive function). However, in participants with more baseline fatigue, those treated with armodafinil did better than those who received the placebo on the end-RT assessments for several outcomes. CONCLUSION:Armodafinil 150 mg/day was well tolerated in primary brain tumor patients undergoing RT with good compliance. While there was no overall significant effect on fatigue, those with greater baseline fatigue experienced improved QOL and reduced fatigue when using armodafinil. These data suggest that a prospective, phase III randomized trial is warranted for patients with greater baseline fatigue.
RCT Entities:
BACKGROUND: Common acute-term side effects of brain radiotherapy (RT) include fatigue, drowsiness, decreased physical functioning, and decreased quality of life (QOL). We hypothesized that armodafinil (a wakefulness-promoting drug known to reduce fatigue and increase cognitive function in breast cancerpatients receiving chemotherapy) would result in reduced fatigue and sleepiness for patients receiving brain RT. METHODS: A phase II, multi-institutional, placebo-controlled randomized trial assessed feasibility of armodafinil 150 mg/day in participants receiving brain RT, from whom we obtained estimates of variability for fatigue, sleepiness, QOL, cognitive function, and treatment effect. RESULTS: From September 20, 2010, to October 20, 2012, 54 participants enrolled with 80% retention and 94% self-reported compliance. There were no grade 4-5 toxicities, and the incidence of grade 2-3 toxicities was similar between treatment arms, the most common of which were anxiety and nausea (15%), headaches (19%), and insomnia (20%). There were no statistically significant differences in end-RT or 4 week post-RT outcomes between armodafinil and placebo in any outcomes (Functional Assessment of Chronic Illness Therapy [FACIT]-Fatigue, Brief Fatigue Inventory, Epworth Sleepiness Scale, FACT-Brain, and FACIT-cognitive function). However, in participants with more baseline fatigue, those treated with armodafinil did better than those who received the placebo on the end-RT assessments for several outcomes. CONCLUSION:Armodafinil 150 mg/day was well tolerated in primary brain tumorpatients undergoing RT with good compliance. While there was no overall significant effect on fatigue, those with greater baseline fatigue experienced improved QOL and reduced fatigue when using armodafinil. These data suggest that a prospective, phase III randomized trial is warranted for patients with greater baseline fatigue.
Authors: K Gehring; S Y Patwardhan; R Collins; M D Groves; C J Etzel; C A Meyers; J S Wefel Journal: J Neurooncol Date: 2011-10-02 Impact factor: 4.130
Authors: Paul D Brown; Karla V Ballman; Teresa A Rummans; Matthew J Maurer; Jeff A Sloan; Bradley F Boeve; Lalit Gupta; David F Tang-Wai; Robert M Arusell; Matthew M Clark; Jan C Buckner Journal: J Neurooncol Date: 2006-02 Impact factor: 4.130
Authors: Berend J Slotman; Murielle E Mauer; Andrew Bottomley; Corinne Faivre-Finn; Gijs W P M Kramer; Elaine M Rankin; Michael Snee; Matthew Hatton; Pieter E Postmus; Laurence Collette; Suresh Senan Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Florien W Boele; Linda Douw; Marjolein de Groot; Hinke F van Thuijl; Wilmy Cleijne; Jan J Heimans; Martin J B Taphoorn; Jaap C Reijneveld; Martin Klein Journal: Neuro Oncol Date: 2013-08-07 Impact factor: 12.300
Authors: Sadhna Kohli; Susan G Fisher; Yolande Tra; M Jacob Adams; Mark E Mapstone; Keith A Wesnes; Joseph A Roscoe; Gary R Morrow Journal: Cancer Date: 2009-06-15 Impact factor: 6.860
Authors: Christina K Cramer; Tiffany L Cummings; Rachel N Andrews; Roy Strowd; Stephen R Rapp; Edward G Shaw; Michael D Chan; Glenn J Lesser Journal: Curr Treat Options Oncol Date: 2019-04-08
Authors: Eudocia Q Lee; Alona Muzikansky; Jan Drappatz; Santosh Kesari; Eric T Wong; Camilo E Fadul; David A Reardon; Andrew D Norden; Lakshmi Nayak; Mikael L Rinne; Brian M Alexander; Nils D Arvold; Lisa Doherty; Jennifer Stefanik; Debra LaFrankie; Sandra F Ruland; Julee Pulverenti; Katrina H Smith; Sarah C Gaffey; Samantha Hammond; Patrick Y Wen Journal: Neuro Oncol Date: 2016-02-21 Impact factor: 12.300
Authors: Katherine B Peters; Mary L Affronti; Sarah Woodring; Eric Lipp; Patrick Healy; James E Herndon; Elizabeth S Miller; Maria W Freeman; Dina M Randazzo; Annick Desjardins; Henry S Friedman Journal: Support Care Cancer Date: 2022-01-10 Impact factor: 3.603
Authors: D Tomlinson; P D Robinson; S Oberoi; D Cataudella; N Culos-Reed; H Davis; N Duong; F Gibson; M Götte; P Hinds; S L Nijhof; P van der Torre; S Cabral; L L Dupuis; L Sung Journal: Curr Oncol Date: 2018-04-30 Impact factor: 3.677